The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
The Effect of Platelet-Rich Plasma Formulations and Blood Products on Human Synoviocytes: Implications for Intra-articular Injury and Therapy
Open accessAbstract
Background: The effect of platelet-rich plasma (PRP) on chondrocytes has been studied in cell and tissue culture, but considerably less attention has been given to the effect of PRP on synoviocytes. Fibroblast-like synoviocytes (FLS) compose 80% of the normal human synovium and produce cytokines and matrix metalloproteinases that can mediate cartilage catabolism. Purpose: To compare the effects of leukocyte-rich PRP (LR-PRP), leukocyte-poor PRP (LP-PRP), red blood cell (RBC) concentrate, and platelet-poor plasma (PPP) on human FLS to determine whether leukocyte and erythrocyte concentrations of PRP formulations differentially affect the production of inflammatory mediators. Study Design: Controlled laboratory study. Methods: Peripheral blood was obtained from 4 donors and processed to create LR-PRP, LP-PRP, RBCs, and PPP. Human synoviocytes were cultured for 96 hours with the respective experimental conditions using standard laboratory conditions. Cell viability and inflammatory mediator production were then evaluated. Results: Treatment with LR-PRP resulted in significantly greater synoviocyte death (4.9% ± 3.1%) compared with LP-PRP (0.72% ± 0.70%; P = .035), phosphate-buffered saline (PBS) (0.39% ± 0.27%; P = .018), and PPP (0.26% ± 0.30%; P = .013). Synoviocytes treated with RBC concentrate demonstrated significantly greater cell death (12.5% ± 6.9%) compared with PBS ( P < .001), PPP ( P < .001), LP-PRP ( P < .001), and LR-PRP (4.9% ± 3.1%; P < .001). Interleukin (IL)–1β content was significantly higher in cultures treated with LR-PRP (1.53 ± 0.86 pg/mL) compared with those treated with PBS (0.22 ± 0.295 pg/mL; P < .001), PPP (0.11 ± 0.179 pg/mL; P < .001), and RBCs (0.64 ± 0.58 pg/mL; P = .001). IL-6 content was also higher with LR-PRP (32,097.82 ± 22,844.300 pg/mL) treatment in all other groups ( P < .001). Tumor necrosis factor–α levels were greatest in LP-PRP (9.97 ± 3.110 pg/mL), and this was significantly greater compared with all other culture conditions ( P < .001). Interferon-γ levels were greatest in RBCs (64.34 ± 22.987 pg/mL) and significantly greater than all other culture conditions ( P < .001). Conclusion: Treatment of synovial cells with LR-PRP and RBCs resulted in significant cell death and proinflammatory mediator production. Clinical Relevance: Clinicians should consider using leukocyte-poor, RBC-free formulations of PRP when administering intra-articularly.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis.
Keffer, J., Probert, L., Cazlaris, H., Georgopoulos, S., Kaslaris, E., Kioussis, D., & Kollias, G. (1991) · The EMBO Journal · doi:10.1002/j.1460-2075.1991.tb04978.x · Cited by 1,660
Treatment of Chronic Elbow Tendinosis with Buffered Platelet-Rich Plasma
Mishra, A., & Pavelko, T. (2006) · The American Journal of Sports Medicine · doi:10.1177/0363546506288850 · Cited by 913
Patel, S., Dhillon, M. S., Aggarwal, S., Marwaha, N., & Jain, A. (2013) · The American Journal of Sports Medicine · doi:10.1177/0363546512471299 · Cited by 762
Horai, R., Saijo, S., Tanioka, H., Nakae, S., Sudo, K., Okahara, A., Ikuse, T., Asano, M., & Iwakura, Y. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.2.313 · Cited by 749
Kon, E., Mandelbaum, B., Buda, R., Filardo, G., Delcogliano, M., Timoncini, A., Fornasari, P. M., Giannini, S., & Marcacci, M. (2011) · Arthroscopy: The Journal of Arthroscopic & Related Surgery · doi:10.1016/j.arthro.2011.05.011 · Cited by 582
Kon, E., Buda, R., Filardo, G., Di Martino, A., Timoncini, A., Cenacchi, A., Fornasari, P. M., Giannini, S., & Marcacci, M. (2010) · Knee Surgery, Sports Traumatology, Arthroscopy · doi:10.1007/s00167-009-0940-8 · Cited by 570
Filardo, G., Kon, E., Buda, R., Timoncini, A., Di Martino, A., Cenacchi, A., Fornasari, P. M., Giannini, S., & Marcacci, M. (2011) · Knee Surgery, Sports Traumatology, Arthroscopy · doi:10.1007/s00167-010-1238-6 · Cited by 475
Platelet-Rich Plasma Releasate Inhibits Inflammatory Processes in Osteoarthritic Chondrocytes
van Buul, G. M., Koevoet, W. L. M., Kops, N., Bos, P. K., Verhaar, J. A. N., Weinans, H., Bernsen, M. R., & van Osch, G. J. V. M. (2011) · The American Journal of Sports Medicine · doi:10.1177/0363546511419278 · Cited by 407
Mor, A., Abramson, S. B., & Pillinger, M. H. (2005) · Clinical Immunology · doi:10.1016/j.clim.2004.12.009 · Cited by 399
Spaková, T., Rosocha, J., Lacko, M., Harvanová, D., & Gharaibeh, A. (2012) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/phm.0b013e3182aab72 · Cited by 389
Cited by
Filardo, G., Previtali, D., Napoli, F., Candrian, C., Zaffagnini, S., & Grassi, A. (2021) · CARTILAGE · doi:10.1177/1947603520931170 · Cited by 294
Autologous Protein Solution Injections for the Treatment of Knee Osteoarthritis: 3-Year Results
Kon, E., Engebretsen, L., Verdonk, P., Nehrer, S., & Filardo, G. (2020) · The American Journal of Sports Medicine · doi:10.1177/0363546520944891 · Cited by 48
Metadata
- Authors
- Braun, H. J., Kim, H. J., Chu, C. R., & Dragoo, J. L.
- Venue
- The American Journal of Sports Medicine
- Publisher
- SAGE Publications
- Published
- 2014-03-14
- Volume
- 42
- Issue
- 5
- Pages
- 1204-1210
- ISSN
- 0363-5465 (ISSN-L)
- 1552-3365
- OpenAlex
- W2123166289
- Cited by
- 287
- References
- 31
- FWCI
- 25.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Effect of Platelet-Rich Plasma Formulations and Blood Products on Human Synoviocytes: Implications for Intra-articular Injury and Therapy. https://app.cochat.ai/papers/10.1177/0363546514525593
- The paper
- Braun, H. J., Kim, H. J., Chu, C. R., & Dragoo, J. L. (2014). The Effect of Platelet-Rich Plasma Formulations and Blood Products on Human Synoviocytes: Implications for Intra-articular Injury and Therapy. The American Journal of Sports Medicine. https://doi.org/10.1177/0363546514525593
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.